Mei-Yu Lv
Impact in
-
- Nanoparticle-Based Drug Delivery
- Supramolecular Self-Assembly in Materials
-
- Nanoplatforms for cancer theranostics
Papers in
-
- RNA Interference and Gene Delivery 2
- Advanced biosensing and bioanalysis techniques 2
- Ubiquitin and proteasome pathways 1
-
- Nanoplatforms for cancer theranostics 6
- Co-authors
- Shoude Jin (8 shared papers)Dong‐Bing Cheng (6 shared papers)Da‐Yong Hou (7 shared papers)Zhiheng Li (3 shared papers)Xingjie Hu (3 shared papers)Xiangpeng Li (5 shared papers)Wanhai Xu (5 shared papers)Hao Wang (2 shared papers)
- Journals
- ACS Nano (2 papers)International Journal of COPD (2 papers)Nature Communications (1 paper)INTERNATIONAL JOURNAL ON Advances in Information Sciences and Service Sciences (1 paper)Nano Letters (1 paper)
- Partner nations
- ChinaNew ZealandHong Kong
In The Last Decade
Mei-Yu Lv
21 papers receiving 283 citations
Mei-Yu Lv's Hit Papers
Peers
Comparison fields: 5 of 60
- Biomaterials 65
- Biomedical Engineering 102
- Pulmonary and Respiratory Medicine 59
- Cancer Research 23
- Molecular Biology 91
Countries citing papers authored by Mei-Yu Lv
This map shows the geographic impact of Mei-Yu Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei-Yu Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei-Yu Lv more than expected).
Fields of papers citing papers by Mei-Yu Lv
This network shows the impact of papers produced by Mei-Yu Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei-Yu Lv. The network helps show where Mei-Yu Lv may publish in the future.
Co-authors
The 25 scholars most cited alongside Mei-Yu Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy Hit paper breakdown → | 2024 | 75 |
| 2 | 2022 | 43 | |
| 3 | 2022 | 32 | |
| 4 | 2022 | 20 | |
| 5 | 2022 | 18 | |
| 6 | 2021 | 15 | |
| 7 | 2024 | 13 | |
| 8 | 2024 | 10 | |
| 9 | 2022 | 10 | |
| 10 | 2022 | 9 | |
| 11 | 2024 | 8 | |
| 12 | 2022 | 8 | |
| 13 | 2024 | 6 | |
| 14 | 2025 | 5 | |
| 15 | 2023 | 4 | |
| 16 | 2021 | 4 | |
| 17 | 2024 | 3 | |
| 18 | 2014 | 3 | |
| 19 | 2012 | 2 | |
| 20 | 2022 | 1 |
About Mei-Yu Lv
Mei-Yu Lv is a scholar working on Molecular Biology, Biomedical Engineering, Pulmonary and Respiratory Medicine, Biomaterials and Oncology, having authored 21 papers that have together received 290 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (6 papers), Nanoparticle-Based Drug Delivery (3 papers), RNA Interference and Gene Delivery (2 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (2 papers), Advanced biosensing and bioanalysis techniques (2 papers), Biomarkers in Disease Mechanisms (1 paper), Ferroptosis and cancer prognosis (1 paper) and Ubiquitin and proteasome pathways (1 paper). The work is most often cited by research in Biomaterials (65 citations), Biomedical Engineering (102 citations), Pulmonary and Respiratory Medicine (59 citations), Cancer Research (23 citations) and Molecular Biology (91 citations). Mei-Yu Lv has collaborated with scholars based in China, New Zealand and Hong Kong. Frequent co-authors include Shoude Jin, Dong‐Bing Cheng, Da‐Yong Hou, Zhiheng Li, Xingjie Hu, Xiangpeng Li, Wanhai Xu, Hao Wang, Taolei Sun and Yuepeng Zhang. Their work appears in journals such as ACS Nano, International Journal of COPD, Nature Communications, INTERNATIONAL JOURNAL ON Advances in Information Sciences and Service Sciences and Nano Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.